MTIS 2022: Atogepant Safe, Effective for Chronic Migraine Prevention
Compared with placebo, atogepant led to reductions in mean monthly migraine days
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Compared with placebo, atogepant led to reductions in mean monthly migraine days
Only registered members have full access to PracticeUpdate content.